Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
- PMID: 17960431
- DOI: 10.1007/s00520-007-0347-3
Performance of a modified MASCC index score for identifying low-risk febrile neutropenic cancer patients
Abstract
Goals of work: This is a prospective and observational study comparing the efficacy of risk-assessment models in patients with neutropenic fever in a reference treatment center. The meaning of the complex infection was evaluated.
Materials and methods: Patients were recruited throughout a 9-month period. Inclusion criteria were histologic diagnosis of malignancy, neutropenic febrile secondary to chemotherapy and/or radiotherapy (absolute neutrophil count of <500/microl and axillary temperature > or = 38 degrees C), and > or = 18 years of age.
Main results: Fifty-three febrile neutropenic patients were included. Twenty one of them were classified as low risk by the Multinational Association of Supportive Care in Cancer (MASCC) risk-index score. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of the MASCC risk-index scores were, respectively 87.9, 85.0, 90.6, 80.9, and 86.8%. None of the low-risk patients died, but four patients classified as low risk by the MASCC model developed serious medical complications during febrile neutropenic episodes. When we subtracted patients with complex infections from the group of patients with the MASCC risk-index score of > or = 21, we got 15 patients that were classified as low risk by a proposed adjustment by complex infection (PACI) model. None of them developed serious medical complications. The sensitivity, specificity, PPV, NPV, and the accuracy of this new model were, respectively, 100, 75.0, 86.8, 100, and 90.6%.
Conclusion: The MASCC risk-index score had high sensitivity and specificity to predict the absence of complications, but the PACI model was better than MASCC for predicting the absence of complications in this febrile neutropenic patients.
Similar articles
-
Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.Support Care Cancer. 2004 Aug;12(8):555-60. doi: 10.1007/s00520-004-0614-5. Epub 2004 Jun 9. Support Care Cancer. 2004. PMID: 15197637
-
Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.Support Care Cancer. 2018 May;26(5):1465-1470. doi: 10.1007/s00520-017-3985-0. Epub 2017 Nov 22. Support Care Cancer. 2018. PMID: 29168032
-
Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?Support Care Cancer. 2011 Jul;19(7):1001-8. doi: 10.1007/s00520-010-0925-7. Epub 2010 Jul 2. Support Care Cancer. 2011. PMID: 20596732
-
Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2020 May;149:102922. doi: 10.1016/j.critrevonc.2020.102922. Epub 2020 Mar 3. Crit Rev Oncol Hematol. 2020. PMID: 32244162
-
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients.Support Care Cancer. 2013 May;21(5):1487-95. doi: 10.1007/s00520-013-1758-y. Epub 2013 Feb 27. Support Care Cancer. 2013. PMID: 23443617 Review.
Cited by
-
Febrile neutropenia studies in Brazil - treatment and cost management based on analyses of cases.Rev Bras Hematol Hemoter. 2013;35(1):3-4. doi: 10.5581/1516-8484.20130002. Rev Bras Hematol Hemoter. 2013. PMID: 23580872 Free PMC article. No abstract available.
-
A proposal for a simplified MASCC score.Support Care Cancer. 2013 Apr;21(4):915-6. doi: 10.1007/s00520-012-1676-4. Epub 2012 Dec 18. Support Care Cancer. 2013. PMID: 23247772 No abstract available.
-
Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis.Cancer Res Treat. 2015 Jul;47(3):448-57. doi: 10.4143/crt.2014.034. Epub 2014 Nov 3. Cancer Res Treat. 2015. PMID: 25648098 Free PMC article.
-
The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas.Support Care Cancer. 2017 Sep;25(9):2815-2822. doi: 10.1007/s00520-017-3696-6. Epub 2017 Apr 11. Support Care Cancer. 2017. PMID: 28401314
-
Detection and Control of Biofilm Formation by Staphylococcus aureus from Febrile Neutropenic Patient.Infect Drug Resist. 2020 Sep 7;13:3091-3101. doi: 10.2147/IDR.S259914. eCollection 2020. Infect Drug Resist. 2020. PMID: 32982324 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials